How can I determine whether a patient with APOE ε3/ε4 genotype is eligible for lecanemab (Leqembi) therapy?

APOE ε3/ε4 Patients Are Eligible for Leqembi (Lecanemab) Therapy

Patients with APOE ε3/ε4 genotype (heterozygotes) can receive lecanemab therapy, as they are not excluded by FDA approval or appropriate use recommendations. The critical distinction is that only APOE ε4 homozygotes (ε4/ε4) face restrictions or require heightened caution, while heterozygotes like your ε3/ε4 patient fall into an intermediate-risk category that permits treatment with appropriate monitoring 1.

Determining Eligibility: Step-by-Step Approach

1. Confirm APOE Genotype Status

• APOE genotyping must be performed before initiating lecanemab to stratify ARIA (Amyloid-Related Imaging Abnormalities) risk 1
• Your patient's ε3/ε4 status places them in the heterozygote category
• Risk stratification by genotype 1:
  • ε4/ε4 homozygotes: 45% ARIA incidence (9% symptomatic ARIA-E)
  • ε3/ε4 heterozygotes: 19% ARIA incidence (2% symptomatic ARIA-E)
  • Non-carriers: 13% ARIA incidence (1% symptomatic ARIA-E)

2. Verify Clinical Eligibility Criteria

The patient must meet these core requirements 1, 2:

• Cognitive stage: Early AD only (MCI due to AD or mild AD dementia)
• Biomarker confirmation: Positive amyloid pathology via PET imaging or CSF biomarkers 3, 4
• Functional status: Community-dwelling with adequate social support

3. Perform Mandatory Pre-Treatment MRI Screening

Critical exclusionary MRI findings that would disqualify treatment 3, 1, 2:

• Hemorrhagic findings:

  • Any intracerebral hemorrhage >10 mm diameter
  • More than 4 microhemorrhages <10 mm diameter
  • Any superficial siderosis (cortical or leptomeningeal)

• Other exclusions:

  • Evidence of vasogenic edema
  • Significant white matter hyperintensities
  • Multiple lacunar infarcts
  • Any infarcts involving major vascular territories
  • Findings suggestive of cerebral amyloid angiopathy (CAA)

Required MRI sequences 3: DWI, T2 FLAIR, and T2* GRE or SWI

4. Assess Medication Contraindications

Anticoagulation is a critical consideration 1, 2:

• Anticoagulants alone or combined with antiplatelet therapy: Intracerebral hemorrhage risk increases to 2.5% (vs. 0.6% without antithrombotics)
• Current recommendation: Patients requiring anticoagulants should NOT receive lecanemab until more safety data are available 2
• Antiplatelet monotherapy (including aspirin): Generally acceptable if on stable dose, though increases bleeding risk modestly 1

5. Exclude Other High-Risk Conditions

Additional clinical exclusions 2:

• Cardiovascular disease requiring active management
• Uncontrolled psychiatric conditions (anxiety, depression)
• Lack of adequate social support for monitoring
• Significant cerebrovascular disease burden

ARIA Monitoring Protocol for ε3/ε4 Patients

Mandatory MRI surveillance schedule 3:

• Baseline MRI within 12 months before treatment initiation
• Follow-up MRIs before the 5th, 7th, and 14th infusions
• Additional MRI any time clinical symptoms suggest ARIA

Clinical symptoms warranting immediate MRI 3, 1:

• Headache, confusion, dizziness
• Visual changes, aphasia
• Focal neurologic deficits
• Seizures
• Gait difficulties

Key Clinical Pitfalls

1. Do not confuse heterozygotes with homozygotes: The European Medicines Agency restricts treatment in ε4/ε4 homozygotes, but this does NOT apply to ε3/ε4 heterozygotes 5. Your patient is eligible under both FDA and EMA frameworks.

2. ARIA-E can mimic ischemic stroke: If your patient develops focal neurologic symptoms during treatment, consider ARIA-E before administering thrombolytic therapy, as tissue plasminogen activator in the setting of ARIA can be fatal 1.

3. Baseline microhemorrhages matter: Even 1-4 microhemorrhages increase ARIA-H risk independently of APOE status 6, 7. Document baseline burden carefully.

4. White matter disease is a predictor: Significant white matter hyperintensities predict both ARIA-H and treatment ineligibility 6, 7. Quantify WMH burden on baseline MRI.

Treatment Decision Framework

Your ε3/ε4 patient can proceed with lecanemab if:

• ✓ Early AD stage confirmed (MCI or mild dementia)
• ✓ Amyloid-positive by PET or CSF
• ✓ Baseline MRI shows ≤4 microhemorrhages, no siderosis, no large hemorrhages
• ✓ Not on anticoagulation (antiplatelet monotherapy acceptable)
• ✓ No significant cerebrovascular disease or other exclusionary findings
• ✓ Adequate support system for monitoring

The heterozygote status confers intermediate risk (19% ARIA vs. 45% in homozygotes), making careful patient selection and monitoring essential but not prohibitive 1, 8. Discuss the 2% risk of symptomatic ARIA-E and the need for frequent MRI surveillance with the patient and care partner before proceeding 2.